Arrivo BioVentures LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arrivo BioVentures LLC - overview
Established
2015
Location
Morrisville, NC, US
Primary Industry
Biotechnology
About
Arrivo BioVentures LLC, based in the US, is focused on developing innovative biopharmaceuticals that target the underlying causes of complex diseases, enhancing treatment options for healthcare providers and patients. Founded in 2015 and headquartered in Morrisville, US, Arrivo BioVentures LLC specializes in biopharmaceutical development. The company has completed 2 deals, with its most recent funding round being a Series B raised on November 17, 2023, amounting to USD 43. 19 mn, led by Orlando Health Ventures.
The firm was co-founded by Michael Ackermann and Stephen Butts, the latter serving as CEO. Arrivo BioVentures does not have any known subsidiaries or parent companies. Arrivo BioVentures is committed to developing innovative biopharmaceuticals addressing the root causes of challenging diseases. Their core product offerings include SP-624, targeting major depressive disorder, and RABI-767, aimed at patients at risk of severe acute pancreatitis.
Both candidates utilize novel mechanisms of action, enhancing their potential effectiveness. The company serves healthcare providers, pharmaceutical partners, and patients primarily in the United States, with plans to expand into global markets as development progresses. The revenue model of Arrivo BioVentures is primarily based on partnerships and collaborations within the pharmaceutical industry. Revenue is generated through strategic alliances, which involve shared costs and profits related to drug development and market entry.
Successful clinical trials for SP-624 or RABI-767 could lead to licensing agreements or joint ventures with larger firms, involving upfront payments, milestone payments, and royalties on future sales, establishing a sustainable financial framework as the products move towards commercialization. In November 2023, Arrivo BioVentures LLC raised USD 43. 19 mn in Series B funding, led by Orlando Health Ventures, to support the advancement of its treatments. This funding will facilitate the progression of SP-624 into late-stage development and advance RABI-767 into Phase 2 trials.
The company is targeting expansions into new global markets as its products develop, aiming to enhance accessibility for patients in need.
Current Investors
Jazz Pharmaceuticals, Inc., Solas BioVentures, Rex Health Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.arrivobio.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Arrivo BioVentures LLC - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.